Bonvalot S. Gronchi A. Le Péchoux C. et al.

Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): A multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol. 21: 1366-1377Bonvalot S. Rutkowski P.L. Thariat J. et al.

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (act.in.sarc): A multicentre, phase 2-3, randomised, controlled trial.

Lancet Oncol. 20: 1148-1159Gronchi A. Palmerini E. Quagliuolo V. et al.

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized trial from italian (ISG), spanish (GEIS), french (FSG), and polish (PSG) sarcoma groups.

J Clin Oncol. 38: 2178-2186Callegaro D. Miceli R. Bonvalot S. et al.

Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: Retrospective analysis across major histological subtypes and major reference centres.

Eur J Cancer. 105: 19-27Lansu J. Bovée J.V.M.G. Braam P. et al.

Dose reduction of preoperative radiotherapy in myxoid liposarcoma: A nonrandomized controlled trial.

JAMA Oncol. 7: e205865Sarcoma Meta-analysis Collaboration (SMAC)

Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults.

Cochrane Database Syst Rev. 4: CD001419Pervaiz N. Colterjohn N. Farrokhyar F. et al.

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.

Cancer. 113: 573-581Pasquali S. Pizzamiglio S. Touati N. et al.

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: Revisiting the results of the EORTC-STBSG 62931 randomised trial.

Eur J Cancer. 109: 51-60Pasquali S. Palmerini E. Quagliuolo V. et al.

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.

Cancer. 128: 85-93Gronchi A. Ferrari S. Quagliuolo V. et al.

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial.

Lancet Oncol. 18: 812-822

DIGITAL FOREST srl. Applestore.

() ()Bonvalot S. Le Pechoux C. De Baere T. et al.

First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas.

Clin Cancer Res. 23: 908-917Wardelmann E. Haas R.L. Bovée J.V. et al.

Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the european organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC-STBSG) recommendations for pathological examination and reporting.

Eur J Cancer. 53: 84-95O'Sullivan B. Davis A.M. Turcotte R. et al.

Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial.

Lancet. 359: 2235-2241Rosenberg S.A. Tepper J. Glatstein E. et al.

The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.

Ann Surg. 196: 305-315Pisters P.W. Harrison L.B. Leung D.H. et al.

Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.

J Clin Oncol. 14: 859-868Yang J.C. Chang A.E. Baker A.R. et al.

Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.

J Clin Oncol. 16: 197-203Beane J.D. Yang J.C. White D. et al.

Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.

Ann Surg Oncol. 21: 2484-2489Davis A.M. O'Sullivan B. Turcotte R. et al.

Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma.

Radiother Oncol. 75: 48-53Kraybill W.G. Harris J. Spiro I.J. et al.

Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514.

J Clin Oncol. 24: 619-625Kraybill W.G. Harris J. Spiro I.J. et al.

Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514.

Cancer. 116: 4613-4621Woll P.J. Reichardt P. Le Cesne A. et al.

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial.

Lancet Oncol. 13: 1045-1054Gronchi A. Stacchiotti S. Verderio P. et al.

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the italian sarcoma group and the spanish sarcoma group.

Ann Oncol. 27: 2283-2288Blanke C.D. Demetri G.D. von Mehren M. et al.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

J Clin Oncol. 26: 620-625Demetri G.D. van Oosterom A.T. Garrett C.R. et al.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial.

Lancet. 368: 1329-1338Demetri G.D. Reichardt P. Kang Y.K. et al.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial.

Lancet. 381: 295-302Blay J.Y. Serrano C. Heinrich M.C. et al.

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet Oncol. 21: 923-934Kang Y.K. George S. Jones R.L. et al.

Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: A randomized, open-label phase III study.

J Clin Oncol. 39: 3128-3139DeMatteo R.P. Lewis J.J. Leung D. et al.

Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival.

Ann Surg. 231: 51-58Joensuu H. Eriksson M. Sundby Hall K. et al.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial.

JAMA. 307: 1265-1272Joensuu H. Eriksson M. Sundby Hall K. et al.

Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: An analysis of a randomized clinical trial after 10-year follow-up.

JAMA Oncol. 6: 1241-1246Dematteo R.P. Ballman K.V. Antonescu C.R. et al.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial.

Lancet. 373: 1097-1104Raut C.P. Espat N.J. Maki R.G. et al.

Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: The PERSIST-5 clinical trial.

JAMA Oncol. 4: e184060Eisenberg B.L. Harris J. Blanke C.D. et al.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665.

J Surg Oncol. 99: 42-47Wang D. Zhang Q. Blanke C.D. et al.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132.

Ann Surg Oncol. 19: 1074-1080Choi H. Charnsangavej C. Faria S.C. et al.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria.

J Clin Oncol. 25: 1753-1759DeMatteo R.P. Ballman K.V. Antonescu C.R. et al.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (alliance) intergroup phase 2 trial.

Ann Surg. 258: 422-429Corless C.L. Ballman K.V. Antonescu C.R. et al.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial.

J Clin Oncol. 32: 1563-1570Joensuu H. Eriksson M. Sundby Hall K. et al.

Adjuvant imatinib for high-risk GI stromal tumor: Analysis of a randomized trial.

J Clin Oncol. 34: 244-250Casali P.G. Le Cesne A. Poveda Velasco A. et al.

Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A european organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the australasian gastro-intestinal trials group, UNICANCER, french sarcoma group, italian sarcoma group, and spanish group for research on sarcomas.

J Clin Oncol. 33: 4276-4283McAuliffe J.C. Hunt K.K. Lazar A.J. et al.

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

Ann Surg Oncol. 16: 910-919Du C.Y. Zhou Y. Song C. et al.

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in china.

Eur J Cancer. 50: 1772-1778Sindelar W.F. Kinsella T.J. Chen P.W. et al.

Intraoperative radiotherapy in retroperitoneal sarcomas. final results of a prospective, randomized, clinical trial.

Arch Surg. 128: 402-410Robertson J.M. Sondak V.K. Weiss S.A. et al.

Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas.

Int J Radiat Oncol Biol Phys. 31: 87-92Jones J.J. Catton C.N. O'Sullivan B. et al.

Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.

Ann Surg Oncol. 9: 346-354Smith M.J. Ridgway P.F. Catton C.N. et al.

Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: Long-term results of a prospective trial.

Radiother Oncol. 110: 165-171Pisters P.W. Ballo M.T. Fenstermacher M.J. et al.

Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.

J Clin Oncol. 21: 3092-3097Roeder F. Ulrich A. Habl G. et al.

Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: Interim analysis.

BMC Cancer. 14 ()Gronchi A. De Paoli A. Dani C. et al.

Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the italian sarcoma group.

Eur J Cancer. 50: 784-792